share_log

B. Riley Securities Reiterates Buy on Journey Medical, Maintains $6 Price Target

Benzinga ·  Sep 7, 2023 08:57

B. Riley Securities analyst Kalpit Patel reiterates Journey Medical (NASDAQ:DERM) with a Buy and maintains $6 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment